Adenovirus-directed expression of dominant negative estrogen receptor induces apoptosis in breast cancer cells and regression of tumors in nude mice. by 이은직
Molecular Medicine 7(11): 773–782, 2001
© 2001 The Picower Institute Press
Adenovirus-directed Expression of Dominant Negative Estrogen
Receptor Induces Apoptosis in Breast Cancer Cells and Regression 
of Tumors in Nude Mice
Eun Jig Lee,1 Monika Jakacka,1 W. Rachel Duan,1 Pei Yu Chien,1 Fred Martinson,1 Barry D. Gehm,1,2
and J. Larry Jameson1,2
1Division of Endocrinology, Metabolism, and Molecular Medicine 
2Robert H. Lurie Comprehensive Cancer Center, Northwestern University Medical School, Chicago, IL, USA 
Accepted October 12, 2001 
Abstract
Background: Estrogen receptors (ER) are expressed in
about two thirds of human breast cancer, and are an im-
portant pharmacological target for treatment of these tu-
mors. Dominant negative forms of the ER have been sug-
gested as an alternative method to disrupt ER function. In
this study, we examined the effect of dominant negative
ER mutants (ER1-536 and L540Q) on ER-positive breast
cancer cells in vitro and in vivo.
Materials and Methods: ER-positive T47D breast cancer
cells were infected with adenoviral vectors expressing
ER1-536 and L540Q to examine the effects of the mutants
on gene expression and cell growth. Adenoviral vectors
containing the wild type ER (AdwtER) and -galactosidase
gene (AdGal) were used as controls.
Results: Ad1-536 or AdL540Q infection inhibited T47D
cell growth and induced apoptosis, increasing Bax protein
and phosphorylation of p38 mitogen-activated-protein
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kinase (MAPK). Consistent with the apoptotic effects in
vitro, pre-infection of T47D cells with Ad1-536 or
AdL540Q inhibited tumor formation when these cells
were introduced into nude mice. In addition, injection of
Ad1-536 and AdL540Q into pre-established T47D tumors
induced tumor regression. Apoptosis, in conjunction with
the activation of caspase-3 and phosphorylation of p38
MAPK, was detected in the shrinking tumors. Over-
expression of wild-type ER by AdwtER infection also pro-
duced antiproliferative and apoptotic effects, but to a
lesser extent than the ER1-536 and L540Q mutants.
Conclusions: These results indicate that dominant nega-
tive ER mutants have the potential to induce apoptosis of
T47D cells and regression of tumors. The delivery of dom-
inant negative ERs by adenoviral vectors may provide a
useful tool for targeted therapy of ER-positive breast
cancer.
Introduction
Estrogens are potent stimulators of breast epithe-
lium proliferation. The presence of estrogen receptor
(ER) in breast cancer is an important prognostic fac-
tor, exceeded in predictive value only by the pres-
ence or absence of axillary lymph node metastasis
(1). About two-thirds of tumors in breast cancer pa-
tients contain high levels of ER protein, and up to
two-thirds of these patients respond to endocrine
ablative therapy (2) or antiestrogen treatment (3–5).
Other modes of disrupting ER function could pro-
vide useful new therapies for breast cancer patients. 
In addition to estrogen receptor antagonists such
as tamoxifen, dominant negative forms of the ER
have been suggested as a method to block ER action
(6–8). These include truncated receptors (ER-1-530
and ER1-536, missing the last 65 or 59 amino acid
residues), a point mutant (L540Q), and a frame shift
mutant (S554fs). Dominant negative ER mutants are
transcriptionally inactive but effectively suppress
wild type transcriptional activity. The formation of
inactive heterodimers, competition for estrogen re-
sponse element (ERE) binding, and speciﬁc tran-
scriptional silencing have been suggested as mecha-
nisms underlying dominant negative activity (9).
Lazennec, et al. (10) demonstrated that adenovirus-
mediated expression of the frame-shifted ER (S554fs)
suppressed the proliferation of ER-positive MCF-7
breast cancer cells. In this study, we used other dom-
inant negative ER mutants (ER1-536 and L540Q) to
examine their effect on gene transcription, cell pro-
liferation, and apoptosis in ER-positive T47D breast
cancer cells in vitro and in an in vivo animal xenograft
model.
Materials and Methods
Generation of Transfer Plasmids and Recombinant
Adenoviral Vectors
A cassette containing the human ER(hER) cDNA
(provided by Dr. Pierre Chambon, Université Louis
Pasteur, Strasbourg, France) driven by the cytome-
galovirus (CMV) promoter/enhancer with a simian
virus (SV) 40 polyadenylation (p(A)) sequence was
subcloned into an adenoviral transfer plasmid (11)
based on pcDNA3 (Invitrogen, Carlsbad, CA). The
dominant negative ERs, 1-536hER and L540QhER
were created using site-directed mutagenesis, and
exchanged for the wild type ER in the adenoviral
transfer plasmid. The resulting plasmids, pCwER,
pC1-536, and pCL540Q, were used to generate re-
combinant adenoviruses. Linearized transfer plas-
mids containing the expression cassette and 393 bp
of 5’ adenoviral sequence were ligated with ClaI-
digested Ad5 309/356 DNA representing map units
3.0-100. (Ad5 309/356 is a recombinant adenovirus
in which the E3 region is deleted. ClaI digestion
removes the E1a region, resulting in a replication-
deﬁcient virus.) The ligation products were trans-
fected into HEK293 cells, in which cellular expres-
sion of the E1a protein allows replication of the 
E1-deleted recombinant viruses. The puriﬁcation
and titration of adenoviral vectors were performed
by plaque assay. Recombinant adenoviruses carry-
ing wild-type hER, 1-536hER and L540QhER
were designated AdwtER, Ad1-536, and AdL540Q,
respectively. AdGal, which contains -galactosidase
driven by CMV promoter, was used as a control. 
An adenoviral reporter vector, AdERE-Luc, was
created to investigate transcriptional activity of the
wild type or dominant negative ER expressed by
adenoviral vectors. The ERE2-TK109 promoter se-
quence was excised from ERE2-tk109-luc (12) and
ligated into pGL3-promoter plasmid (Promega,
Madison, WI) from which the SV40 promoter had
been deleted (NheI to HindIII). Then a portion of
the resulting plasmid, containing the upstream syn-
thetic p(A) signal, two consensus EREs, a 109 bp
fragment of the thymidine kinase promoter, the
ﬁreﬂy luciferase gene, and the downstream SV40
p(A) signal, was subcloned into the adenoviral
transfer plasmid. The resulting plasmid, pC-ERE-
Luc, was used to generate AdERE-Luc. The se-
quences of the expression cassettes in the adenovi-
ral vectors were conﬁrmed by automated DNA
sequencing. Structures of the adenoviral vectors are
shown in Fig. 1.
Cell Culture and Infection of Recombinant Adenoviruses
ER-positive T47D and ER-negative MDA-MB-231
breast cancer cells were provided by Dr. V. Craig
Jordan (Northwestern University Medical School,
Chicago, IL) and cultured in DMEM/F12  10% fetal
bovine serum (FBS). HEK293 embryonic kidney cells
were obtained from the American Type Culture Col-
lection (Rockville, MD) and maintained in DMEM 
10% FBS. All media were supplemented with
100 units/ml penicillin and 100 g/ml streptomycin;
all cells were maintained at 37C with 5% CO2.
For infection of adenoviral vectors, cells were
depleted of estrogen for 3 days using phenol red-
free DMEM/F12 containing 5% dextran/charcoal-
stripped FBS (DCC-FBS). Transduction efﬁciency of
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adenoviral vectors in cell lines was tested using Ad-
Gal. -galactosidase expression was detected in 95-
to 100% of T47D cells at 48 hours after infection
with AdGal at a multiplicity of infection (MOI) of 5
plaque-forming units (PFU) per cell (data not
shown). MDA-MB-231 cells showed 95- to 100%
expression at 10 PFU/cell (data not shown). There-
fore, subsequent experiments were done using sim-
ilar amounts (5 or 10 PFU/cell) of recombinant ade-
noviral vectors.
The transcriptional activities of ER and dominant
negative ER were assayed on the 2ERE-TK109-lu-
ciferase reporter gene as described previously (12).
Brieﬂy, 12-well plates of T47D cells were infected
with 1 PFU/cell AdERE-Luc and increasing amounts
(1, 5, and 10 PFU/cell) of AdGal, AdwtER, Ad1-536,
and AdL540Q overnight. Fresh media containing E2
was added, further incubation continued for 24 h,
and then luciferase activity was assayed.
Immunoﬂuorescence, Immunohistochemistry, and Terminal
Deoxynucleotidyltransferase (TdT)-Mediated UTP End
Labeling (TUNEL) Assays 
To detect the expression of ER delivered by aden-
oviral vector, MDA-MB-231 cells were collected
and mounted on slides 48 h after infection with
adenoviral vectors. After 10 min air-drying, cells
were ﬁxed with ice-cold methanol followed by ace-
tone (5 min each). After preincubation with serum
blocking solution (ABC kit, Vector Laboratories,
Inc., Burlingame, CA) for 10 min, slides were incu-
bated with mouse monoclonal anti-human ER
(1:50, D-12, sc-8005, Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA) for 2 h at room temperature. After
Fig. 1. Structures of recombinant adenoviruses. The aden-
oviral vector contains a backbone derived from adenovirus 
type 5 (Ad5 309/356), in which the E3 region has been deleted.
The genes of interest (shaded area) were inserted in place of
the E1 region. Five different recombinant adenoviral vectors
were generated: AdwtER, Ad1-536, AdL540Q, AdGal, and
AdERE-Luc. AdGal, which contains the -galactosidase gene
driven by the CMV promoter, was used to determine the efﬁ-
ciency of gene transduction and as a control for non-speciﬁc
effects of infection. AdERE-Luc, which carries 2 estrogen
response elements, the minimal thymidine kinase promoter
(109 bp) (2ERE-TK109), and the ﬁreﬂy luciferase gene, was
used to measure ER transcriptional activity in infected cells.
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antibody (1:5000, Promega, Madison, WI) and the en-
hanced chemiluminescence system (Amershan Phar-
macia Biotech, Arlington Heights, IL). Bands were de-
tected with Kodak (Rochester, NY) X-Omat ﬁlm.
Cell Proliferation Assays
The effect of dominant negative ER on T47D cell
growth was measured with a nonradioactive cell
proliferation assay according to the manufacturer’s
protocol (Cell Titer 96 Aqueous Non-Radioactive Cell
Proliferation Assay, Promega, Madison, WI). Cells
were seeded in 96-well plates at a density of 5  103
cells/well and infected on the following day with ade-
noviral vectors at different MOIs (0, 5, 10 PFU/cell).
Medium was replaced at 5 h after infection and every
two days thereafter. To measure the effect of different
doses of E2 (1, 10, and 100 nM), quadruplicate wells
were assayed for viable cell density at day 6. Relative
density was calculated as the absorbance at 490 nm of
the virus infected cells divided by that of the 1 nM E2-
treated cells, and expressed as a percentage (mean 
SD). In a second set of experiments, cell density was
assayed at 2-day intervals over an 8 day-period with a
ﬁxed E2 concentration (1 nM). 
Analysis of T47D Tumors in Nude Mice
Two different experimental designs were used. To
study tumor formation, T47D cells were infected with
5 PFU/cell of adenoviruses and incubated at 37C for
24 h. Cells were collected, washed twice with PBS, re-
suspended in medium and injected (2  106 cells) into
the ﬂanks of adult (8-week old) athymic female nude
mice (Harlan-Sprague-Dawley, Indianapolis, IN),
which had been subcutaneously implanted with 
60-day estrogen pellets (Innovative Research of
America, Sarasota, FL) 7 days earlier. The mice were
divided into 5 different groups (6 injection sites per
group): 1) no virus; 2) AdGal; 3) AdwtER; 4) Ad1-
536; 5) AdL540Q. Animals were examined for tumor
formation and growth for a period of 3 weeks. 
In a second design, the effect of dominant negative
ER on pre-established T47D tumors in nude mice was
investigated. T47D cells (1  107) were injected into
the ﬂank areas of estrogen pre-implanted nude mice.
Ten days after injection, tumors of about 6–7 mm
diameter had developed and the mice were divided
into 4 groups (6 tumors per group), each of which was
injected with a different adenoviral vector: AdGal,
AdwtER, Ad1-536, or AdL540Q. Doses of 5  109 PFU
were injected into the tumors on 3 successive days,
from three different directions. The sizes of the tumors
in all three dimensions were measured twice a week
with calipers. Tumor size (mm3) was calculated using
the formula: (3.14  length  width  depth)6. The
experiment was terminated 3 weeks after injection of
adenoviral vectors. 
Results were subjected to analysis of variance
and the statistical signiﬁcance of differences be-
tween treatment groups was evaluated by Tukey’s
-test. To investigate the histologic changes in
washing with TBS/ 0.025% Tween, staining was
performed using biotinylated secondary antibodies
(ABC kit, Vector Laboratories) and streptavidin-
FITC (1:100, Vector Laboratories).
To detect apoptosis of T47D cells infected with
adenovirus, cells were collected after 6 d of estro-
gen treatment, mounted on glass slides, air-dried
for 10 min, ﬁxed for 30 min in 4% paraformalde-
hyde, and permeabilized with buffer containing
0.1% sodium citrate and 0.4% Triton-X 100 for 
2 min on ice. The cells were then washed with PBS
and subjected to a modiﬁed TdT-mediated ﬂuores-
cein-dUTP nick end labeling (TUNEL) reaction using
the In Situ Cell Death Detection Kit, Fluorescein
(Boehringer-Mannheim Co. Indianapolis, IN).
To detect the activation of p38 MAPK and
caspase-3 in T47D tumors excised from nude mice, 
4 m sections of tumor in parafﬁn block were pre-
pared. After deparafﬁnization, slides were placed in a
jar containing 10 mM sodium citrate buffer (pH 6.0),
exposed to microwave radiation (1000 W) for 5 min,
and cooled to room temperature. After preincubation
with serum blocking solution, slides were incubated
with rabbit polyclonal anti-phospho-p38MAPK,
anti-p38MAPK (1:100, New England Biolabs, Inc.
Beverly, MA), and rabbit polyclonal anti-cleaved cas-
pase-3 (1:50, Cell Signaling Technology, Inc, Beverly,
MA), respectively for 1 h at room temperature. After
washing with TBS/0.025% Tween, staining was per-
formed using ABC kit (Vector Laboratories). Images
were obtained using a Nikon Eclipse E400 micro-
scope (NIKON Co., Tokyo, Japan).
Western Blot Analyses
Cells were plated in 10 cm culture dishes at a density
of 5.0  106 cells/plate. The next day, cells were in-
fected with adenoviral vectors at a MOI of 5 PFU/cell
for 5 h. After addition of fresh media, the cells were
incubated for 48 h with or without 1 nM estradiol.
Cells were washed twice with PBS, and whole cell
lysates (ER, Bax, and Bcl-2) or nuclear protein ex-
tracts (phospho-p38 MAPK) were prepared as de-
scribed previously (13). Samples containing equal
amounts of protein were resolved by 10% SDS-PAGE
and transferred onto nitrocellulose ﬁlters. The mem-
branes were blocked with 5% nonfat milk in PBS for
1.5 h and then incubated overnight at 4C with pri-
mary antibodies. For the detection of ER, mouse
monoclonal anti-human ER (D-12, sc-8005, 1:400,
Santa Cruz Biotechnology, Inc.) was used. Mouse
monoclonal anti-Bcl-2 (1:1000, Santa Cruz Biotech-
nology, Inc.), and mouse monoclonal anti-Bax
(1:1000, Santa Cruz Biotechnology, Inc.) were used
for the detection of apoptosis regulatory proteins. Ac-
tivated p38MAPK (Thr180/Tyr182-phosphorylated
p38MAPK) was detected by rabbit polyclonal anti-
phospho-p38MAPK (1:1000, New England Biolabs).
After three washes in 0.1% Tween-20 in PBS,
immunoreactive proteins were detected using an anti-
mouse or rabbit horseradish peroxidase-conjugated
shrinking tumors, tumors were removed from a sec-
ond group of mice 7 days after injection of adenovi-
ral vectors and embedded in parafﬁn. All studies 
involving the use of nude mice were approved by
the Northwestern University Medical School Ani-
mal Care and Use Committee.
Results
Expression of ER Delivered by Adenoviral Vectors
Immunoﬂuorescence was used to observe ER expres-
sion in ER-negative MDA-MB-231 breast cancer cells
infected with adenoviral vectors. AdGal-infected cells
served as a negative control. ER was detected in the
nucleus of cells infected with AdwtER, Ad1-536, and
AdL540Q, but not in the control cells (Fig. 2A). Using
a MOI of 10 PFU/cell, wt or mutant ER expression
was detected in 95% of MDA-MB-231cells. Similar
results were obtained in ER-negative COS-7 cells
(data not shown).
Western blot analyses were also performed to
further characterize expression of the mutants. As
expected, anti-ER immunoreactive bands of approxi-
mately 66 kDa were detected in cells infected with
AdwtER or AdL540Q. Ad1-536 infected cells showed
a band of greater mobility, consistent with the reduced
molecular weight of the 1-536 truncation mutant.
Wild type ER and mutants were expressed at compa-
rable levels. No ER band was detected in cells infected
with AdGal (Fig. 2B). We also compared the expres-
sion levels between endogenous ER and adenovirally
expressed ER in T47D cells. As assessed by Western
blotting, ER levels were about 10-fold greater in T47D
cells infected with 5 PFU/cell, and about 20- to 30-
fold greater with 10 PFU/cell, than endogenous ER
levels in T47D cells (data not shown).
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Fig. 2. Expression of the human ER in MDA-MB-231 
ER-negative breast carcinoma cells infected with
adenoviral vectors. (A) Immunoﬂuorescence localization of
ER in MDA-MB-231 cells. MDA-MB-231 cells infected with
AdGal (a), AdwtER (b), Ad1-536 (c), and AdL540Q (d) were
subjected to immunoﬂuorescence staining with mouse
monoclonal anti-human ER. (B) Western blot analysis of ER.
Whole cell extracts of MDA-MB-231 cells infected with aden-
oviral vectors were analyzed using the same antibody. Similar
results were obtained in a second independent experiment for
both immunoﬂuorescence and Western blotting.
Fig. 3.  Effect of dominant negative ER on transcriptional
activity of the endogenous ER in T47D cells. ER
transcriptional activity was assayed using the estrogen-
responsive luciferase reporter vector described in Materials and
Methods. Triplicate wells of T47D cells were co-infected with 
1 PFU/cell AdERE-Luc and increasing amounts (1, 5, and 
10 PFU/cell) of AdGal, AdwtER, Ad1-536, or AdL540Q. T47D
cells infected with AdERE-Luc alone were used as a control.
After overnight infection, fresh medium containing E2 (1 nM)
was added, cells were incubated for an additional 24 h, and
luciferase activity was assayed. Data are expressed as a
percentage (mean  standard deviation, n  3) of luciferase
activity in control T47D cells treated with E2. Reporter activity
in AdL540Q-infected cells is signiﬁcantly (p  .01) reduced
compared to Ad-Gal infected cells at MOIs of 5 and 
10 PFU/cell; activity in Ad1-536-infected cells is signiﬁcantly 
(p  .01) reduced compared to AdGal- and L540Q-infected
cells at all MOIs. Similar results were obtained in two
additional independent experiments.
Effect of Dominant Negative ERs on the Transcriptional
Activity of the Endogenous ER in T47D Cells
To investigate whether dominant negative ER expres-
sion by adenovirus infection affects endogenous ER
activation of estrogen-responsive reporter genes,
T47D cells were co-infected with AdERE-Luc and
adenoviruses encoding wt or dominant negative ERs.
As shown in Fig. 3, E2 (1 nM) treatment stimulated
ERE reporter gene activity about 20-fold over back-
ground in control (uninfected and AdGal-infected)
cells. AdwtER infection at an MOI of 1 PFU/cell in-
creased reporter response two-fold, but higher doses
of AdwtER produced no further increase. In contrast,
infection with adenoviral vectors expressing domi-
nant negative ERs suppressed the estrogen-stimulated
activity in a dose-dependent manner. This suppres-
sion was greater in cells infected with Ad1-536 (91%
and 95% at 5 and 10 PFU/cell respectively) than
AdL540Q (44% and 70%). 
Effect of Dominant Negative ER on T47D 
Cell Growth in Vitro
To investigate whether dominant negative ERs inﬂu-
ence cell growth, the proliferation of T47D cells was
examined after infection with two different doses 
(5 and 10 PFU/cell) of adenoviral vectors. As shown
in Figs. 4A and B, growth of uninfected cells was
stimulated by 6-day E2 treatment (1–100 nM). Ad1-
536 or AdL540Q infection suppressed E2-stimulated
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days are required for the mutant receptors to exert
an inhibitory effect.
Effect of Dominant Negative ERs on Induction of Apoptosis,
Bax and Bcl-2 Expression, and Activation of p38 MAPK 
in T47D Cells
TUNEL assays for DNA fragmentation were used to
investigate whether dominant negative ERs induce
apoptosis (14). A positive TUNEL reaction was ob-
tained in T47D cells infected with Ad1-536 (51.1 
6.2%) and AdL540Q (46.1  3.4%). AdwtER infec-
tion also induced apoptosis, but the TUNEL positiv-
ity (15.1  3.7%) was lower (Fig. 5 B, C, D; percent-
ages represent means  s.d. of 4 microscope ﬁelds for
each vector). The TUNEL reaction was negative in
AdGal infected cells (Fig. 5A) and uninfected cells,
regardless of estrogen treatment (data not shown). 
Western blotting was used to examine the ex-
pression of speciﬁc proteins associated with apopto-
sis. T47D cells were infected with adenoviral vectors
and treated with E2 for 48 h or 72 h. Cells infected
with AdwtER, Ad1-536, or AdL540Q showed in-
creased expression of the pro-apoptotic Bax protein
(Fig. 6A). Estrogen treatment increased expression of
the anti-apoptotic protein Bcl-2 at 48 h and 72 h in un-
infected cells, but infection with dominant negative
ER vectors signiﬁcantly decreased Bcl-2 expression.
growth by 60–85%, depending on the mutant and
viral dose. AdGal had little effect on the growth of
T47D cells. Infection with AdwtER at 5 PFU/cell
caused a modest increase (50%) in growth in the
absence of added E2, possibly by enhancing the
effectiveness of trace levels of estrogens remaining
in the stripped serum. However, in the presence of
added E2, slight growth inhibition (25% to 30%)
was observed. Using a MOI 10 PFU/cell, AdwtER
produced a more substantial (70%) inhibition of
E2-stimulated cell growth, and no growth increase
in the absence of E2.
To assess the time course of these effects, T47D
cells were infected with adenoviral vectors, and
assayed for cell density every two days thereafter
for a total of 8 days (Fig. 4C, D). Initially all cells
proliferated in response to E2 (1nM). Growth in-
hibition by Ad1-536 or AdL540Q was apparent by
day 4 or 6. AdwtER had little effect on cell growth
at 5 PFU/cell, while 10 PFU/cell inhibited growth
more, but not as much as the dominant negative
ER mutants. Growth was not affected by the Ad-
Gal virus, implying that growth inhibition was not
due to nonspeciﬁc effects of viral infection. These
results indicate that virally expressed dominant
negative ER mutants can inhibit estrogen-stimu-
lated growth of breast cancer cells, but several
Fig. 4.  Effect of dominant negative ER on the growth of T47D cells. Cells were plated, infected and treated as described in
Materials and Methods. After treatment for 6 days with various doses of E2 (A, B), or at intervals over an 8-day treatment with
1 nM E2 (C, D), cell growth was determined by a colorimetric assay. For panels A and B, cell density is expressed as a percentage,
normalized to E2 treated (1 nM) uninfected cells. All results are plotted as means  standard deviations for quadruplicate wells.
Similar results were obtained in two additional experiments.
At 72 h, a slight decrease in Bcl-2 expression was also
observed in AdwtER-infected cells (Fig. 6B).
Activation of p38 MAPK kinase is associated with
4-hydroxytamoxifen-induced apoptosis in MCF-7
breast cancer cells (15). To analyze the effect dominant
negative ERs on p38 MAPK activation, nuclear pro-
tein extracts were prepared from adenovirus-infected
T47D cells treated with E2 over a range of times (0, 6,
12, 24, and 48 h), and extracts were analyzed by
Western blotting with anti-phospho-p38 antibody
(Fig 6C). Phosphorylation of p38 MAPK occurred most
rapidly (by 24 h) and intensely in Ad1-536-infected
cells. After 48 hr, phospho-p38 was also detectable in
AdL540Q-infected cells and, at much lower levels, in
AdwtER-infected cells. No phospho-p38 was detected
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in extracts from uninfected cells or cells infected with
the AdGal control vector. 
Effect of Dominant Negative ERs on T47D Tumors
in Nude Mice
Based on the ﬁndings that dominant negative ERs
inhibit cell growth and induce apoptosis in vitro, we
tested whether expression of dominant negative ERs
would inhibit tumor formation by ER positive
breast cancer cells in nude mice. T47D cells, either
uninfected or infected with the various adenoviral
expression vectors, were injected subcutaneously
into estrogen-treated female athymic mice. Within
10 days, tumors formed in animals injected with
uninfected cells (5 of 6 injection sites) or AdGal
infected cells (6 of 6 sites). The tumors continued
to grow and attained sizes of 44  17 mm3 and 29 
8 mm3, respectively, 3 weeks after injection (Fig. 7A).
In contrast, no tumors were detected, either by palpa-
tion or post-mortem histopathological examination,
Fig. 5.  Induction of positive TUNEL reaction. T47D cells
were infected with AdGal (A), AdwtER (B), Ad1-536 (C), and
AdL540Q (D) at an MOI of 5 PFU/cell. After 6 days of
treatment with E2 (1 nM), the TUNEL assay was performed.
Fluorescence (white) indicates TUNEL labeling. AdGal-infected
cells were also stained with DAPI (violet) to show cell density.
Fig. 6.  Expression of Bax and Bcl-2, and activation of
caspase-3 and p38 MAPK in T47D cells. Cells were infected
with 5 PFU/cell of adenoviral vectors and treated with E2 over a
range of times. Equal amounts of whole cell extracts (Bax, and
Bcl-2) or nuclear extract (phospho-p38 MAPK) were resolved by
SDS/PAGE and immunoblotted with mouse monoclonal 
antibodies against Bax (A), Bcl-2 (B), or phospho-p38MAPK 
(C). Similar results were obtained in two additional experiments. 
Fig. 7.  Effect of dominant negative ER on T47D cell
growth in vivo. (A) The effect of dominant negative ER on
tumor formation by T47D cells in nude mice. T47D cells were
infected with adenoviral vectors and injected into nude mice
as described in Materials and Methods. Tumor volume was
measured after 3 weeks. Each bar represents the mean 
standard error (S.E.) of tumor volumes; numbers in paren-
thees indicate the number of tumors formed per 6 injection
sites. The difference between uninfected and AdGal groups
was not signiﬁcant (p  .05). (B) Anti-tumor effect of domi-
nant negative ER on pre-established T47D cell tumors in
nude mice. Tumors were injected with adenoviral vectors as
described in Materials and Methods. The tumor sizes were
measured twice a week for 3 weeks. Tumor volume is pre-
sented as mm3, mean  S.E. for each treatment group. Points
showing a statistically signiﬁcant difference from AdGal are
marked (#:  [experimentwise error rate]  0.05; *:   0.01).
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nuclei, in AdwtER, Ad1-536 or AdL540Q injected
tumors (Fig. 8B–D). In addition, necrosis was ob-
served in Ad1-536 injected tumors (Fig. 8C). In con-
trast, AdGal-injected tumor tissue showed no such
features (Fig. 8A). TUNEL assays for DNA fragmenta-
tion revealed widespread areas of apoptosis in tumors
injected with AdwtER, Ad1-536 or AdL540Q (Fig.
8E–G). Immunohistochemical staining showed that
cleaved caspase-3 is present in the AdwtER, Ad1-536,
and AdL540Q injected tumors, but not AdGal-in-
jected controls (Fig. 8I–L). Similar results were ob-
tained in tumor sections stained for phospho-p38
MAPK (Fig. 8M–P). Double labeling of slices from an
AdL540Q-injected tumor showed that most cells that
stained positive for phospho-p38 MAPK also exhib-
ited a positive TUNEL reaction (data not shown).
These histological results indicate that the tumor
regression produced by injection of dominant nega-
tive ER-expressing adenoviruses is due to induction
of apoptosis in the tumor cells, mediated at least in
part by p38 MAPK and caspase-3.
Discussion
Lazennec et al. (10) demonstrated that adenovirus-
mediated expression of the dominant negative ER
in the animals injected with cells infected with
AdwtER, Ad1-536, or AdL540Q.
We also investigated the effect of dominant neg-
ative ERs introduced into pre-existing T47D tumors
in nude mice. Mice were injected with uninfected
cells as described above. When the tumor diameters
reached about 6 to 7 mm, each group (n  6 tumors)
received daily intratumoral injections of adenoviral
vectors for 3 days. Injection of adenoviruses encod-
ing dominant negative ERs (Ad1-536 or AdL540Q)
induced tumor regression, whereas AdGal injection
did not (Fig. 7B). The difference between the domi-
nant negative ER mutants and the control vector
was statistically signiﬁcant ( [experimentwise er-
ror rate] 0.01 for 1-536 and 0.05 for L540Q at
day 21). Although tumors injected with AdwtER
showed signiﬁcant growth suppression at day 11
(  0.05 compared to AdGal), they regrew, and
the difference between the AdwtER and control
(AdGal) groups was not signiﬁcant at later times. 
To determine the mode of cell death, adenoviral
vectors were injected into T47D cell tumors in a sepa-
rate group of mice, and tumor tissue was examined 
7 days later. Microscopic examination of hematoxylin-
eosin stained tissue revealed features of apoptosis,
including shrinkage of cells and condensation of
Fig. 8.  Apoptotic effect of dominant negative ER on T47D tumor xenografts. Seven days after injection of adenoviral vectors
into T47D tumors in nude mice, tumors were removed and embedded in parafﬁn. Hematoxylin-eosin (H&E) staining, TUNEL assays
and immunohistochemistry for cleaved caspase-3 and phospho-p38 MAPK were performed as described in Materials and Methods on
tumors injected with AdGal (A, E, I, M), AdwtER (B, F, J, N), Ad1-536 (C, G, K, O) and AdL540Q (D, H, L, P). All panels are
shown at 1000 magniﬁcation. (A–D): H&E stained sections. (E–H): TUNEL assay (green ﬂuorescence indicates positive reaction). 
(I–L): Immunostaining for cleaved caspase-3 (brown indicates presence of antigen). (M–P): Immunostaining for phospho-p38 MAPK
(brown indicates presence of antigen). Three tumors from each treatment group were sectioned and tested with similar results.
mutant S554fs in MCF-7 cells in vitro inhibited the
transcriptional activity of the endogenous ER, blocked
estrogen-stimulated cell growth, and increased the
proportion of cells undergoing apoptosis. In this
study, we extend these observations by using two
other dominant negative ERs (1-536 and L540Q) in
T47D cells, another ER-positive breast cancer line.
In addition, we demonstrate that infection with ade-
noviral vectors carrying these mutants blocks in vivo
tumor formation and induces regression of estab-
lished tumors. 
Cells infected with wild-type ER also showed
reduced growth and increased apoptosis in the
presence of estrogen compared to uninfected or
AdGal-infected cells. Moreover, pre-infection with
AdwtER blocked tumor formation by T47D cells
injected into nude mice. These results were not en-
tirely unexpected because previous studies have
shown signiﬁcant growth inhibition in cells tran-
siently or stably transfected with ER cells (16–21).
In addition, Lazennec et al., examined the effect of
adenovirus expressed wtER on cell proliferation in
two different breast cancer cell types. In MDA-
MB-231 cells, which lack endogenous ER, wtER
signiﬁcantly inhibited proliferation in the pres-
ence of estrogen (22). In MCF-7 cells, which ex-
press a very high level of endogenous ER, inhibi-
tion was more modest and occurred only at a high
MOI (10). In T47D cells, which express a lower
level of endogenous ER than MCF-7 cells, we ob-
served modest inhibition of proliferation by
AdwtER at an MOI of 5 PFU/cell, and a more sub-
stantial inhibition at a higher MOI. The differ-
ences in these results are probably due to the dif-
ferent cell lines used and may reﬂect the different
levels of endogenous ER expression.
Programmed cell death, or apoptosis, plays an
important role in maintaining cellular homeostasis to
ensure the balance between the rate of cellular prolif-
eration and cell loss. Important genetic elements in
this mechanism are Bcl-2 family proteins, including
the anti-apoptotic proteins Bcl-2, Bcl-X, and Mcl-1,
and the pro-apoptotic protein Bax (23,24). Bax over-
expression in breast cancer cells increases sensitivity
to stressful stimuli, with resultant decreased cell sur-
vival and increased apoptosis (25). The ratio of Bcl-2
to Bax, rather than the absolute levels of either pro-
tein, may regulate the apoptotic response (26). Bcl-2
expression has been associated with the presence of
ER in breast cancer cells (27–29). Several studies
showed that patients whose tumors co-expressed
ER and Bcl-2 have enhanced responses to endocrine
therapy (27,30,31). Bcl-2 is an estrogen-regulated
protein. Bcl-2 transcription is up-regulated by estro-
gen and down-regulated by antiestrogens in ER
positive MCF-7 and T47D human breast cancer cells,
whereas Bax is not (32–36). Bcl-2 up-regulation is
mediated by the presence of 2 ERE sequences in the
coding region of the Bcl-2 gene (37). As expected,
expression of dominant negative ERs reduced the
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levels of Bcl-2 protein in estrogen-treated T47D cells.
It also increased expression of the pro-apoptotic Bax
protein. These results suggest that down-regulation
of Bcl-2 and up-regulation of Bax may be involved in
the induction of apoptosis by dominant negative ERs
in T47D cells. Infection with AdwtER had little or no
effect on Bcl-2 expression but increased Bax protein
levels. However, AdwtER was less effective for in-
ducing other markers of apoptosis (described below)
and for blocking tumor formation and growth. The
full role of Bax and Bcl-2 in the estrogen regulation of
apoptosis in these cells remains to be determined.
Overexpression of wtER may also inhibit prolif-
eration by non-apoptotic mechanisms. In MDA-MB-
231 cells, growth inhibition by adenoviral expression
of wtER was correlated with decreased expression of
c-myc, BRCA1 and BRCA2 (22), which are proto-
oncogenes or cancer susceptibility genes. It is also
possible that high levels of ER titrate transcription fac-
tors that are necessary for cell proliferation, or induce
expression of estrogen-regulated growth-inhibitory/
cytotoxic genes.
Recently, activation of the p38 MAPK pathway
was demonstrated in HeLa-ER5 cells (which are sta-
bly transfected with ER) induced to undergo apopto-
sis by treatment with E2 or 4-hydroxytamoxifen
(OHT) (15). In MCF-7 cells, which express ER en-
dogenously, OHT also induces both p38 MAPK acti-
vation and apoptosis. In both cell types, the p38
MAPK inhibitor SB203580 protects against E2- or
OHT-induced apoptosis. These results are consistent
with our observations that phosphorylation of p38
MAPK is associated with the induction of apoptosis
by dominant negative ERs and, to a lesser extent,
wtER in T47D cells, both in vitro and in tumor
xenografts. Activation of p38 MAPK stimulates phos-
phorylation and activation of p53 (38,39), a protein
that regulates genes involved in cell cycle progression
and apoptosis (40). However, T47D cells express an
inactive mutant p53 (41,42), suggesting that another,
still-unknown, pathway connects p38 MAPK activa-
tion and apoptosis in these cells. 
Caspase-3 is a key component of the apoptotic
pathway, catalyzing the proteolytic degradation of
several crucial target proteins (43). Activation of cas-
pase-3, which results from proteolytic cleavage of its
inactive zymogen into active p17 and p12 subunits
(44), occurs during tamoxifen-induced apoptosis of
MDA-MB-231 and BT-20 cells breast cancer cells
(45). In the present studies using the T47D xenograft
model, activation of the caspase-3 cascade was ob-
served in AdwtER, Ad1-536, and AdL540Q injected
tumors. These results indicate that tumor regression
produced by injection of wt or dominant negative
ER-expressing adenoviruses is associated with
apoptosis in the tumor cells, mediated at least in
part by caspase-3.
In addition to using adenovirally expressed
dominant negative ERs to inhibit cell proliferation
and induce apoptosis in vitro, we demonstrated their
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effectiveness in vivo, using human breast cancer
xenografts in nude mice. Infection of T47D cells
with dominant negative ER vectors prior to injection
into the mice completely abolished tumor formation.
More importantly, injection of these vectors into pre-
established tumors induced regression. Histologic
studies revealed apoptosis in the regressing tumors,
as indicated by changes in nuclear morphology,
DNA fragmentation, and activation of p38 MAPK
and caspase-3. Infection with control adenovirus
produced no such effects, and infection with virus
encoding wtER produced only transient regression.
These results indicate that dominant negative ER
mutants exert growth arrest and apoptosis in ER-
positive breast cancer cells. Adenovirus-mediated
delivery of these mutants may provide an alternative
modality for targeted therapy of human breast cancer. 
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